RAND's divisions conduct research on a uniquely broad front for clients around the globe.
Most relevant regions
Research
Jan 1, 2008
The authors performed a cross-cultural comparison of sexual function and bother in men with localized prostate cancer in the United States and Japan.
Evaluates patterns of quality of life in men with both prostate cancer and cardiovascular disease during followup for cancer survivors. These patients have worse physical and sexual health-related quality of life before and following treatment.
Initial Prostate Cancer Outcomes Study (PCOS results revealed that 2 years after radical prostatectomy more than 90% of men were continent and about half were by some definition potent.
Japanese men were much less likely to use phosphodiesterase-5 (PDE-5) inhibitors than were U.S. men after radical prostatectomy, despite reporting worse sexual function scores. Cultural differences in patterns of PDE-5 inhibitor use were evident.
Finds differing recovery patterns for urinary dysfunction and associated distress during the first two years after radical prostatectomy or external beam radiation therapy for Japanese and U.S. men with localized prostate cancer.
Shares insights from the landmark National Institutes of Health-funded Chronic Prostatitis Collaborative Research Network studies, which have improved management of chronic prostatitis/chronic pelvic pain syndrome.
Prostate cancer patients with moderate to severe cardiovascular disease (CVD) have worse health-related quality of life during follow-up. Those with severe CVD recover their physical and sexual functioning more slowly after treatment.
Finds significant and unwarranted variations for prostate cancer care quality indicators by census division and hospital type, which illustrate the inconsistencies in prostate cancer care and represent potential targets for quality improvement.
Jan 1, 2007
Men denied enrollment into the IMPACT program exhibited worse symptom distress and self-efficacy compared to enrolled men at initial assessment.
Among the challenges that face physicians who care for men with prostate cancer is evaluating the patient's potential for benefiting from treatment.
The authors ascertained the health care costs of androgen deprivation therapy and related skeletal events.
The use of androgen deprivation therapy (ADT) in the treatment of men with prostate cancer has risen sharply.